US Top News and Analysis
Food and snack companies may feel the most pressure as weight-loss drugs become more mainstream and impact consumer behaviors, according to Bank of America. Diabetes drugs that mimic gut hormones such as glucagon-like peptide-1, or GLP-1, have found new audiences in people looking to lose weight. In some instances, people taking these medicines have reported less of a hankering for unhealthy foods or alcohol and other drinks. Analyst Geoff Meacham noted there are many unknowns about what the impact of the drugs on consumer behavior will look like in the long term. But he said the highest risk is to alcohol, snacking and beverage products. Weight-management products like shakes or frozen meals could also be pressured, Meacham added. On the other hand, he said restaurants will likely feel less impacted as the pros of eating out such as convenience, taste and sociability won’t change. CNBC Pro compiled some of the stocks that could be at risk that the firm is watching. All data is from LSEG and current as of Friday morning: — CNBC’s Michael Bloom contributed to this report
Author Profile
Latest entries
- HeadlinesOctober 19, 2024Rosie O’Donnell’s daughter Chelsea arrested for child neglect, drug possession
- ScienceOctober 19, 2024Social media policies are no match for AI bots
- HeadlinesOctober 19, 2024Mets survive Game 5 vs. Dodgers to send NLCS back to Los Angeles
- HeadlinesOctober 19, 2024College admissions officer rails against Trump supporters in social media post: 'Piece of s—'